
Bristol-Myers Squibb has halted a mid-stage trial of a new Hepatitis C drug due to major safety concerns. In a …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

